Posterior Reversible Encephalopathy Syndrome after Solid Organ Transplantation

References

1. ↵
   Truwit CL, Denaro CP, Lake JR, et al. MR imaging of reversible cyclosporin A-induced neurotoxicity. AJNR Am J Neuroradiol 1991;12:651–59

   Abstract/FREE Full Text
2. ↵
   Bartynski WS, Grabb BC, Zeigler Z, et al. Watershed imaging features and clinical vascular injury in cyclosporin A neurotoxicity. J Comput Assist Tomogr 1997;21:872–80

   CrossRefPubMed
3. ↵
   Bartynski WS, Zeigler Z, Spearman MP, et al. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol 2001;22:1901–14

   Abstract/FREE Full Text
4. ↵
   Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 2002;23:1038–48

   Abstract/FREE Full Text
5. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500

   CrossRefPubMedWeb of Science
6. ↵
   Mukherjee P, McKinstry RC. Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology 2001;219:756–65

   CrossRefPubMedWeb of Science
7. ↵
   Provenzale JM, Petrella JR, Cruz LC Jr, et al. Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2001;22:1455–61

   Abstract/FREE Full Text
8. ↵
   Besenski N, Rumboldt Z, Emovon O, et al. Brain MR imaging abnormalities in kidney transplant recipients. AJNR Am J Neuroradiol 2005;26:2282–89

   Abstract/FREE Full Text
9. ↵
   Appignani BA, Bhadelia RA, Blacklow SC, et al. Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. AJR Am J Roentgenol 1996;166:683–88

   PubMedWeb of Science
10. Kaczmarek I, Groetzner J, Meiser B, et al. Impairment of the blood-brain barrier can result in tacrolimus-induced reversible leucoencephalopathy following heart transplantation. Clin Transplant 2003;17:469–72

    CrossRefPubMed
11. Lischke R, Simonek J, Stolz AJ, et al. Cyclosporine-related neurotoxicity in a patient after bilateral lung transplantation for cystic fibrosis. Transplant Proc 2004;36:2837–39

    CrossRefPubMed
12. Parvex P, Pinsk M, Bell LE, et al. Reversible encephalopathy associated with tacrolimus in pediatric renal transplants. Pediatr Nephrol 2001;16:537–42

    CrossRefPubMedWeb of Science
13. Thyagarajan GK, Cobanoglu A, Johnston W. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. Ann Thorac Surg 1997;64:1461–64

    CrossRefPubMedWeb of Science
14. ↵
    Bartynski WS, Sanghvi A. Neuroimaging of delayed eclampsia. Report of 3 cases and review of the literature. J Comput Assist Tomogr 2003;27:699–713

    CrossRefPubMedWeb of Science
15. Ito T, Sakai T, Inagawa S, et al. MR angiography of cerebral vasospasm in preeclampsia. AJNR Am J Neuroradiol 1995;16:1344–46

    Abstract
16. ↵
    Schaefer PW, Buonanno FS, Gonzalez RG, et al. Diffusion-weighted imaging discriminates between cytotoxic and vasogenic edema in a patient with eclampsia. Stroke 1997;28:1082–85

    Abstract/FREE Full Text
17. ↵
    Singh N, Bonham A, Fukui M. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. Transplantation 2000;69:467–72

    CrossRefPubMedWeb of Science
18. ↵
    Bartynski WS, Boardman JF, Zeigler ZR, et al. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol 2006;27:2179–90

    Abstract/FREE Full Text
19. ↵
    Schwartz RB, Bravo SM, Klufas RA, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995;165:627–31

    CrossRefPubMedWeb of Science
20. Kur JK, Esdaile JM. Posterior reversible encephalopathy syndrome–an underrecognized manifestation of systemic lupus erythematosus. J Rheumatol 2006;33:2178–83

    Abstract/FREE Full Text
21. Poon WL, Mok CC. Reversible posterior leucoencephalopathy in scleroderma. Ann Rheum Dis 2005;64:1803–04

    FREE Full Text
22. ↵
    Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980–82; discussion 980–982

    CrossRefPubMedWeb of Science
23. Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998;19:415–17

    Abstract
24. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980–82; discussion 980–982

    CrossRefPubMedWeb of Science
25. Patel AG, Rao R. Transient Ara-C leukoencephalopathy: MR findings. J Comput Assist Tomogr 1996;20:161–62

    PubMed
26. Rippe DJ, Edwards MK, Schrodt JF, et al. Reversible cerebral lesions associated with tiazofurin usage: MR demonstration. J Comput Assist Tomogr 1988;12:1078–81

    PubMed
27. ↵
    Russell MT, Nassif AS, Cacayorin ED, et al. Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging 2001;19:129–32

    CrossRefPubMedWeb of Science
28. ↵
    Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999;246:339–46

    CrossRefPubMedWeb of Science
29. ↵
    Ay H, Buonanno FS, Schaefer PW, et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 1998;51:1369–76

    Abstract/FREE Full Text
30. ↵
    Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990;163:1049–54; discussion 1054–55

    CrossRefPubMedWeb of Science
31. ↵
    Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007;28:1320–27

    Abstract/FREE Full Text
32. ↵
    Bartynski WS, Zeigler ZR, Shadduck RK, et al. Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. AJNR Am J Neuroradiol 2004;25:261–69

    Abstract/FREE Full Text
33. ↵
    Furlong T, Storb R, Anasetti C, et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000;26:985–91

    CrossRefPubMed
34. ↵
    Jain A, Brody D, Hamad I, et al. Conversion to Neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. Transplantation 2000;69:172–76

    CrossRefPubMedWeb of Science
35. ↵
    Brubaker LM, Smith JK, Lee YZ, et al. Hemodynamic and permeability changes in posterior reversible encephalopathy syndrome measured by dynamic susceptibility perfusion-weighted MR imaging. AJNR Am J Neuroradiol 2005;26:825–30

    Abstract/FREE Full Text
36. Engelter ST, Provenzale JM, Petrella JR. Assessment of vasogenic edema in eclampsia using diffusion imaging. Neuroradiology 2000;42:818–20

    CrossRefPubMedWeb of Science
37. Naidu K, Moodley J, Corr P, et al. Single photon emission and cerebral computerised tomographic scan and transcranial Doppler sonographic findings in eclampsia. Br J Obstet Gynaecol 1997;104:1165–72

    PubMedWeb of Science
38. Lin JT, Wang SJ, Fuh JL, et al. Prolonged reversible vasospasm in cyclosporin A-induced encephalopathy. AJNR Am J Neuroradiol 2003;24:102–04

    Abstract/FREE Full Text
39. Raps EC, Galetta SL, Broderick M, et al. Delayed peripartum vasculopathy: cerebral eclampsia revisited. Ann Neurol 1993;33:222–25

    CrossRefPubMedWeb of Science
40. Trommer BL, Homer D, Mikhael MA. Cerebral vasospasm and eclampsia. Stroke 1988;19:326–29

    Abstract/FREE Full Text
41. ↵
    Raroque HG, Jr., Orrison WW, Rosenberg GA. Neurologic involvement in toxemia of pregnancy: reversible MRI lesions. Neurology 1990;40:167–69

    Abstract/FREE Full Text
42. ↵
    Bonham CA, Dominguez EA, Fukui MB, et al. Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation 1998;66:1596–604

    CrossRefPubMedWeb of Science
43. ↵
    Cilio MR, Danhaive O, Gadisseux JF, et al. Unusual cyclosporin related neurological complications in recipients of liver transplants. Arch Dis Child 1993;68:405–07

    Abstract/FREE Full Text
44. ↵
    Bohlin AB, Berg U, Englund M, et al. Central nervous system complications in children treated with ciclosporin after renal transplantation. Child Nephrol Urol 1990;10:225–30

    PubMed
45. de Groen PC, Aksamit AJ, Rakela J, et al. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 1987;317:861–66

    CrossRefPubMedWeb of Science
46. ↵
    Deierhoi MH, Kalayoglu M, Sollinger HW, et al. Cyclosporine neurotoxicity in liver transplant recipients: report of three cases. Transplant Proc 1988;20:116–18

    PubMedWeb of Science
47. ↵
    Reece DE, Frei-Lahr DA, Shepherd JD, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant 1991;8:393–401

    PubMedWeb of Science
48. ↵
    Zimmer WE, Hourihane JM, Wang HZ, et al. The effect of human leukocyte antigen disparity on cyclosporine neurotoxicity after allogeneic bone marrow transplantation. AJNR Am J Neuroradiol 1998;19:601–08; discussion 609–10

    Abstract
49. ↵
    Bartynski WS, Zeigler ZR, Shadduck RK, et al. Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoietic malignancies and marrow conditions after allogeneic bone marrow transplantation. Neurocrit Care 2005;3:33–45

    CrossRefPubMed
50. ↵
    Burt RK, Wilson WH. Conditioning (preparative) regimens. In: Burt RK, Deeg HJ, Lothian ST, Santos GW, eds. Bone Marrow Transplant. Georgetown, Tex: Landes Bioscience;1996 :94–108
51. ↵
    Ferrara JL. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 2000;9:299–306

    CrossRefPubMed
52. ↵
    Chew NJ. Graft-versus-host disease. In: Burt RK, Deeg HJ, Lothian ST, et al, eds. Bone Marrow Transplant. Georgetown, Tex: Landes Bioscience;1996;478–98
53. ↵
    Burt RK, Walsh TJ. Infection prophylaxix in bone marrow transplant recipients- myths, legends and microbes. In: Burt RK, Deeg HJ, Lothian ST, et al, eds. Bone Marrow Transplant. Georgetown, Tex: Landes Bioscience;1996 :438–51
54. ↵
    Goodman WG, Danovitch GM. Options for patients with kidney failure. In: Danovitch GM, ed. Handbook of Kidney Transplantation 4th ed. Philadelphia: Lippincott Williams & Wilkins;2005 :1–22
55. ↵
    Singer J, Gritsch HA, Rosenthal JT. The transplant operation and its surgical complications. In: Danovitch GM, ed. Handbook of Kidney Transplantation 4th ed. Philadelphia: Lippincott Williams & Wilkins;2005 :193–211
56. ↵
    Katznelson S, Terasaki PI, Danovitch GM. Tissue typing, crossmatching and the allocation of cadaveric kidney transplants. In: Hakim NS, Danovitch GM, eds. Transplantation Surgery. London: Springer-Verlag;2001 :43–54
57. ↵
    Halloran PF, Batiuk TD, Goes N, et al. Immunologic concepts. In: Stuart FP, Abecassis MM, Kaufman DB, eds. Organ Transplantation 2nd ed. Georgetown, Texas: Landes Bioscience;2003 :1–44
58. Kimball P, King A. Desensitized renal transplant recipients show reduced cellular responses to in vitro challenge. Transplant Proc 2006;38:3416–17

    CrossRefPubMed
59. ↵
    Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995;8:411–26

    Abstract/FREE Full Text
60. ↵
    Munford RS. Sepsis, severe sepsis and septic shock. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia: Elsevier;2005 :906–26
61. ↵
    Keefe EB. Selection of patients for liver transplantation. In: Maddrey WC, Schiff ER, Sorrell MF, eds. Transplantation of the Liver. Philadelphia: Lippincott Williams & Wilkins;2001 :5–34
62. Laffi G, Cominelli F, Ruggiero M, et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988;8:1620–26

    CrossRefPubMedWeb of Science
63. ↵
    Sanchez-Roig MJ, Rivera J, Moraleda JM, et al. Quantitative defect of glycoprotein Ib in severe cirrhotic patients. Am J Hematol 1994;45:10–15

    CrossRefPubMed
64. ↵
    Xu M, Okajima H, Hubscher S, et al. Liver transplantation. In: Hakim NS, Danovitch GM, eds. Transplantation Surgery. London: Springer-Verlag;2001 :181–210
65. ↵
    Everson GT, Kam I. Immediate postoperative care. In: Maddrey WC, Schiff ER, Sorrell MR, eds. Transplantation of the Liver 3rd ed. Philadelphia: Lippincott Williams & Wilkins;2001 :131–62
66. ↵
    Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458–62

    CrossRefPubMedWeb of Science
67. ↵
    Romanovsky AA, Ivanov AI, Szekely M. Neural route of pyrogen signaling to the brain. Clin Infect Dis 2000;31 Suppl 5:S162–67
68. ↵
    Starzl TE, Demetris AJ, Trucco M, et al. Cell migration, chimerism, and graft acceptance, with particular reference to the liver. In: Busuttil RW, Klintmalm G, eds. Transplantation of the Liver. Philadelphia: WB Saunders;1996 :274–87